



Depósito de Investigación
Universidad de Sevilla

Depósito de investigación de la Universidad de Sevilla

<https://idus.us.es/>

“This is an Accepted Manuscript of an article published by Elsevier in:
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
on 2018, available at: <https://doi.org/10.1016/j.ejpb.2018.10.007>”

1 **Early stages of drug crystallization from amorphous solid dispersion via fractal analysis**
2 **based on chemical imaging**

3 Renata Abreu-Villela ^{1,2}, Monica Schönenberger ³, Isidoro Caraballo ¹, Martin Kuentz ²

4
5 ¹Universidad de Sevilla, Department of Pharmacy and Pharmaceutical Technology, C/Profesor García Gon-
6 zález 2, 41012 Seville, Spain.

7 ²University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharma Technology,
8 Hofackerstrasse 30, 4132 Muttenz, Switzerland

9 ³University of Basel, Swiss Nanoscience Institute, Nano Imaging Lab, Klingelbergstrasse 82, 4056 Basel,
10 Switzerland.

11

12

13

14 **Address correspondence to**

15 Prof. Dr. Martin Kuentz

16 University of Applied Sciences and Arts Northwestern Switzerland

17 Institute of Pharma Technology

18 Hofackerstr. 30

19 4132 Muttenz / Switzerland

20 T +41 (61) - 228 56 42

21 martin.kuentz@fhnw.ch

22

23

24

25 **Abstract**

26 Early stages of crystallization from amorphous solid dispersion (ASD) are typically not detected by means
27 of standard methods like powder X-ray diffraction (XRPD). The aim of this study is therefore to evaluate
28 if fractal analysis based on energy dispersive x-ray imaging can provide the means to identify early signs
29 of physical instability. ASDs of the poorly water-soluble compound, felodipine (FEL) were prepared by
30 solvent evaporation using different grades of HPMCAS, at 50wt. % drug loading. Samples were stored at
31 accelerated conditions of 40°C. Scanning electron microscopy equipped with an energy-dispersive X-ray
32 spectroscopy (SEM-EDS) was used for elemental mapping of tablet surfaces. Comparative data were gen-
33 erated with a standard XRPD and with more sensitive methods for detection of early instability, i.e. laser
34 scanning confocal microscopy (LSM) and atomic force microscopy (AFM). The SEM-EDS identified
35 changes of drug-rich domains that were confirmed by LSM and AFM. Early changes in drug clusters were
36 also revealed by a multifractal analysis that indicated a beginning phase separation and drug crystallization.
37 Therefore, the presented fractal cluster analysis based on chemical imaging bears much promise as a new
38 method to detect early signs of physical instability in ASD, which is of great relevance for pharmaceutical
39 development.

40

41 **Keywords:** solid dispersion; amorphous drug; phase separation; crystallization; chemical imaging; mul-
42 tifractal analysis

43

44

45 **1. Introduction**

46 Amorphous solid dispersion (ASD) has become an established oral delivery technique to formulate poorly
47 water-soluble drugs [1–3]. Given the large number of papers that are published on solid dispersions, it is
48 rather surprising that there are not many more of these products on the pharmaceutical market [4]. One of
49 the main reasons is that ASDs are metastable systems and bear the risk of physical instability during their
50 shelf life. Drug crystallization can occur depending on the history of an amorphous product and on given
51 conditions [5]. Particularly critical is storage at elevated temperature and moisture leading eventually to
52 phase separation and crystallization, which means a loss of biopharmaceutical advantages using ASD [6–
53 8]. The molecular processes of phase separation as well as crystallization from amorphous material are
54 complex and mobility in the glass state plays an important role. Relaxation of amorphous materials take
55 place on different time scales from primary diffusive (α -relaxation) to secondary local relaxation such as
56 Johari-Goldstein relaxations (β -relaxation). While α -relaxation becomes very slow in the glass state, it is
57 mostly the secondary relaxations that are relevant for crystallization from amorphous state [9–11]. Once
58 crystallization starts, it continues to reduce the system's free energy [12,13]. Thus, thermodynamics is the
59 driver for physical change and molecular mobility is a facilitator, while surface effects can act as modula-
60 tors, and heterogeneities as amplifiers of crystallization [14].

61

62 A standard method to detect and characterize crystalline material is X-ray power diffraction (XRPD) but
63 like with other conventional methods such as differential scanning calorimetry, it is challenging to detect
64 small amounts of crystalline material. Such small amounts can be already present following manufacture
65 of an amorphous product or they are generated as initial instability but either ways, such crystallites can
66 negatively affect kinetic stability of ASDs [12,13].

67

68 Interesting for detection of crystalline material are imaging techniques that can be based on different phys-
69 ical principles. Since amorphous formulations are typically multi-component systems, chemical image has
70 the advantage that an active pharmaceutical ingredient (API) is differentiated from excipients. Any

71 chemical imaging involves a sophisticated analytical technique for acquisition of images and spectra that
72 contain the chemical information [15], which typically enables spatial distribution of one or all formulation
73 components [16]. Images can be acquired at the surface and in the bulk by electron microscopy, such as,
74 transmission electron microscopy (TEM) (Yamada et al., 2017) and scanning electron microscopy (SEM)
75 with energy dispersive X-ray spectroscopy (EDS) [17,18]. Important are also vibrational spectroscopic
76 techniques with appropriate optics, such as Raman [15,19,20], near infrared (NIR), or terahertz spectroscopy
77 [14].

78
79 It is critical for any imaging technique how the large amounts of data are evaluated. Suitable algorithms
80 such as modern chemometric methods can be applied to extract useful information from otherwise just large
81 and incomprehensible data sets [15]. An algorithmic topic in its own right is how clusters are analyzed in
82 images since a naked eye is not capable of detecting any subtle changes of an imaged microstructure. Prom-
83 ising for any such cluster analysis is fractal geometry. This approach was pioneered by Mandelbrot and
84 does not use classical geometry to describe physical objects [21]. Fractal geometry has been applied in
85 pharmaceuticals, for example, to describe a solvent-mediated formation of a drug hydrate [22]. However, a
86 single fractal dimension is often not sufficient to adequately describe a complex heterogeneous system. A
87 more generalized mathematical concept is given by multifractal analysis, which decomposes the self-simi-
88 lar measures into intertwined fractal sets that describe the variations from the average in heterogeneous
89 systems [23].

90
91 Recently, the multifractal formalism was introduced in solid dispersion technology to describe the spatial
92 distribution of an inorganic carrier [24]. In a subsequent work, the distribution of different drugs in ASDs
93 was revealed to have a multifractal character [25]. The mathematical formalism was found to model ade-
94 quately the heterogeneous nature of drug clusters in ASD and a next step would be to study changes over
95 time. The hypothesis of the present work is that multifractal analysis based on chemical imaging can proof
96 utility in analyzing early stages of physical instability. Thus, felodipine (FEL) was used as model drug in
97 solid dispersions with the polymer hydroxypropyl methylcellulose acetate succinate (HPMCAS). The

98 different grades LF and HF were used with 14-18% and 4-8% of succinoyl substitutions, respectively [26].
99 ASDs of FEL/HPMCAS were analyzed topographically by SEM-EDS as a chemical imaging technique,
100 which provided the basis for multifractal analysis. To have a comparison with other known sensitive meth-
101 ods, samples were also studied by laser scanning confocal microscopy (LSM) and atomic force microscopy
102 (AFM).

103

104 **2. Materials and methods**

105 *2.1. Materials*

106 Felodipine (FEL) was purchased from Kemprotec Ltd. (Smailthorn, Cumbria, UK) and the different grades
107 of HPMCAS (Shin-Etsu AQOAT[®], Type LF and HF) were a generous gift from Shin-Etsu Chemical Co.
108 Ltd. (Tokyo, Japan). Dichloromethane and methanol (HPLC grade) were procured from Sigma-Aldrich (St.
109 Louis, Missouri, USA). The API chemical structure as well as monomer units of the polymer are given in
110 Fig. 1. Particularly highlighted are chloride atoms regarding their selective detection by energy dispersive
111 X-ray spectroscopy.

112

113 *2.2. Methods*

114 *2.2.1. Preparation of physical mixtures and solid dispersions by rotary evaporation*

115 Initial pretests of varying drug loads suggested that 50% FEL in polymer was rather challenging for amor-
116 phous stability, which therefore provided a suitable reference concentration in the ASDs of the main study.
117 Binary mixtures of 50% w/w FEL polymer were then prepared by dissolving drug and polymer in a solvent
118 mixture of 50: 50 (v/v) dichloromethane: methanol. All solvent mixtures were visually inspected to confirm
119 that the drug and the polymer were completely dissolved and the systems formed uniform one-phase solu-
120 tions. The solvent was then removed at 50°C under reduced pressure using a rotavapor RE120 (Bünchi
121 Labortechnik AG, Flawil, Switzerland) with a vacuum controller CVC2 (Vacuubrand GMBH + CO,
122 Wertheim, Germany). The obtained solid mass was stored at room temperature overnight to remove any

123 residual solvents. The ASDs were freeze/milled with SPEX SamplePrep model 6770 (Metuchen, New jersey,
124 sey, USA). For a comparison with amorphous formulations, physical mixtures (PM) were prepared by mix-
125 ing the powders of FEL and polymer for 5 minutes with a spatula.

126
127 Samples of the solid dispersions were compressed to tablets for subsequent surface and image analysis.
128 Thus, powders (100 mg) were manually fed into a hydraulic XP1 press (Korsch AG, Berlin, Germany) and
129 manually compacted. The compacts were flat-faced and round with a diameter of 7 mm.

130

131 *2.2.2. X-ray powder diffraction*

132 X-ray powder diffractogram (XRPD) were determined for PM as well as for ASD obtained from rota-
133 evaporation. A D2 Phaser diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) was employed that
134 was equipped with a Co-2K KFL diffraction tube configured and a 1D- Lynxeye detector and with a Fe
135 filter. The applied voltage and current were 30kV and 10mA, respectively. Diffraction patterns were ob-
136 tained using a step width of 0.02° with a detector resolution in 2θ between 6-40° and a scan speed of 2s/step
137 at room temperature.

138

139 *2.2.3. Stability studies*

140 Compacts were stored in hermetically closed glass vials at a temperature of 40°C using a climate chamber
141 (Binder GmnH, Tuttlingen, Germany). The storage temperature was selected as a realistic but accelerating
142 condition to detect kinetic changes over time (e.g. phase separation and/or drug crystallization). Samples
143 were taken at specific time intervals and analyzed physically.

144

145 *2.2.4. Scanning electron microscopy and energy-dispersive X-ray spectroscopy*

146 The samples were placed on double-side adhesive carbon tabs and the surface of the compacts was coated
147 with gold under argon vacuum with a Sputter Coater SC7620 (Quorum Technologies Ltd., Kent, UK).
148 These surfaces were then studied by means of scanning electron microscopy (SEM) TM3030 PLUS (Hita-
149 chi High-Technologies Corporation, Tokyo, Japan) and micrographs were collected in a mix mode. The
150 microscope was equipped with an energy-dispersive X-ray spectroscopy (EDS) device for elemental map-
151 ping. The analysis was based on a Quantax 70 system software (Bruker Nano GmbH, Berlin, Germany)
152 consisting of an X Flash Min SVE signal processing unit, a scan generator and Megalink interface together
153 with an X Flash silicon drift detector 410/30 H (Bruker Nano GmbH, Berlin, Germany). Samples were
154 scanned during 300 seconds at a voltage of 15 kV to map the drug distribution of chloride (Cl) atoms for
155 comparatively higher X-ray scattering intensity. This procedure was performed on all compacts at random
156 location in spot sizes of $113 \times 85 \mu\text{m}^2$.

157

158 *2.2.5. 3D-Laser scanning confocal microscopy*

159 Laser scanning micrographs of the sample surfaces were collected by means of a 3D laser scanning confocal
160 microscopy (LSM) VK-X200 (Keyence, Osaka, Japan) using a violet laser (408nm) and a 150x objective
161 lens (Nikon Plan CF Apo, 150x/0.95, WD 0.2mm) . The surface is scanned at high speed in X, Y and Z,
162 allowing image capturing and height measurements with high lateral resolution. Reflected white light and
163 laser light emitted from the focal point are reflected back through the objective lens. The intensity of the
164 laser light that passes through a pinhole is determined by a very sensitive 16-bit photomultiplier. Since the
165 pinhole blocks most of the returning light (except the light from the focal point), confocal LSM delivers
166 much sharper images than conventional microscopy techniques. In addition, a true color image from the
167 integrated second light source is overlaid.

168

169 *2.2.6. Atomic force microscopy*

170 Atomic force microscopy (AFM) images of compacts were acquired at ambient conditions in dynamic AC
171 mode using a NanoWizard 4 AFM instrument (JPK Instruments AG, Berlin, Germany). Height and phase

172 images were collected simultaneously using a silicon PPP-NCHR cantilever (Nanosensors AG, Neuchâtel,
173 Switzerland) with a resonance frequency of approximately 320 kHz and 42 N m⁻¹ spring constant.

174

175 *2.2.7. Image processing*

176 The CI distribution images were exported to Image J software (National Institutes of Health, Bethesda,
177 Maryland, USA) and converted to maximum intensity projection. In a second step, the gray scale images
178 in the bmp format (with 1023 x 766 pixels and a resolution 72 dpi) were resized to the png format with 512
179 x 512 pixels while keeping the same resolution. The projected images were unsharpened with a radius of
180 12 pixels and they were binarized using MATLAB software package, version R2017b (The MathWorks,
181 Inc., Natick, USA). In a binary image, a signal pixel is defined as a digital element whose intensity is 1
182 after thresholding the images of 5 and this conversion to binary format (with a resolution of 96 dpi) was
183 conducted with 10 images per each sample analysis.

184

185 *2.2.8. Multifractal and statistical data analysis*

186 While classical fractals are mathematical objects with a single fractal dimension, multifractal formalism
187 decomposes self-similar measures into intertwined fractal sets (Gould et al., 2011; Li et al., 2012). A brief
188 review of basic multifractal theory is given in the Appendix.

189

190 Box-counting method algorithm was used to cover a 2-D image for determination of fractal dimensions.
191 Using the binary images, boxes (grids of 512 pixel sizes) were counted using at least one pixel of the
192 observed object. A multifractal spectrum was then determined with a customized MATLAB program as
193 proposed and described previously [27].

194

195 The formalism of multifractals expresses here a generalized fractal dimension or a “deformation parameter”
196 of variability degrees (D_q) and moment order (q) that is a number within $[-\infty; +\infty]$ interval extracting char-
197 acteristics of the cluster distribution [28]. The multifractal spectra or the generalized dimension can be
198 restricted to three values of particular interest D_0 , D_1 and D_2 . Herein, D_0 is the "classical box-counting di-
199 mension" also called the “capacity” dimension and D_1 refers to an information dimension (related to Shan-
200 non’s measure of entropy) and characterizes the degree of disorder in a distribution. Finally, D_2 is named a
201 “correlation” dimension so it indirectly marks a degree of clustering [23,27–30].

202 The obtained fractal dimensions at the different time points were compared statistically by means of an
203 analysis of the variance (ANOVA). STATGRAPHICS Centurion XVI ed. Professional (V. 16.1.15) from
204 Statpoint Technologies Inc. (Warranton, Virginia, USA) was used for all statistical calculations and a p -
205 value < 0.05 was considered as significant. For comparison of the means, Fisher's procedure of the least
206 significant difference (LSD) was calculated for 95% confidence intervals.

207

208 **3. Results**

209 *3.1. Physical characterization*

210 XRPD is a standard method to detect crystalline material based on distinct peaks arising from Bragg scat-
211 tering from defined crystal planes. The absence of diffraction peaks in the initial analysis of solid disper-
212 sions were therefore an indicator of successful amorphization of FEL at a comparatively high load of 50%
213 (w/w). A subsequent storage during four weeks at 40°C did also not lead to samples in which crystalline
214 drug was evidenced so the formulations were still unchanged at least based on XRPD (Figure 2). By con-
215 trast, the analysis following eight weeks of storage (40°C) revealed diffraction peaks of FEL, which was
216 an obvious consequence of re-crystallization from the amorphous solid state. The diffraction peaks in the
217 LF grade appeared to be more pronounced than in case of HF.

218

219 *3.2. Scanning electron microscopy and energy-dispersive X-ray spectroscopy*

220 A suitable way to analyze the chemical distribution of specific atoms (as markers of molecules) on a surface
221 is facilitated by SEM-EDS mapping. It is a qualitative method of chemical imaging and in this study, chlo-
222 ride was studied as characteristic marker of FEL since this was the only Cl-containing component in the
223 formulation. The SEM-EDS binary micrographs of surface topography are presented in Fig. 3. Images of
224 freshly prepared formulations and of those that show rearrangements of clusters over time (at 40°C) are
225 shown. The white pixels hold for the chloride (and hence FEL) distribution and it is possible to see some
226 changes in the degree of clustering. However, only qualitative changes are detectable to a limited extent by
227 the naked eye so that a more quantitative analysis is required to study cluster dynamics for which the mul-
228 tifractal formalism is applied.

229

230 3.3. Multifractal analysis

231 Table 1 shows the results of multifractal analysis in terms of the dimensions with q values from zero to
232 two. The different D_q values were pointing to multifractals as a better model than to assume a simpler
233 monofractal cluster distribution, which would entail a constant D_q . This was even more clearly seen when
234 dimensions at any time point were plotted for a broader range of q values, as a typical sigmoidal shape was
235 evidenced with decreasing D_q along decreasing q values (not shown).

236

237 The capacity dimension D_0 was clearly below two for the Euclidian dimension but still comparatively high
238 suggesting rather dense fractal structures. Values for D_1 and D_2 were also in a similar range as compared to
239 our previous study [25]. The changes over time were focused on the early stage of stability testing, which
240 did not reveal re-crystallization based on classical XRPD testing. However, Table 1 indicates some changes
241 of D_q over time, which were statistically analyzed. An analysis of the variance (ANOVA) was conducted
242 with time and polymer grade as factors and the generalized fractal dimensions (D_0 , D_1 , and D_2) were indeed
243 found to be statistically significant to capture the microstructure changes, with significant p -values ($p <$
244 0.0001) for a time effect regarding any of the three dimensions studied. By contrast, the factor of HPMCAS
245 grade was not found to be significant with respect to D_0 , D_1 , or D_2 . Fig 4 shows a statistical means plot

246 together with Fisher's 95% LSD intervals. The significant storage effect was similar in extent for all fractal
247 dimensions and is shown in Fig. 4 for D_0 as well as for D_2 . The novel approach was obviously capable of
248 identifying microstructural changes even in the early phase of stability testing.

249

250 *3.4. Laser scanning confocal microscopy*

251 LSM provided nondestructive images in a relatively broad microstructural range for the different time
252 points of early stability testing of FEL systems. Fig. 5 shows rather rough surfaces before storage (Fig.
253 5a/b) with hardly any crystals observed. Interestingly, the LSM images after 4 weeks (Fig. 5c/d) suggested
254 generally smoother surfaces with some curved rough regions in the underlying microstructure for both
255 formulations. Either for each system a “blooming” effect was evidenced, which could be interpreted as
256 crystals formed on top of the surface or protruding directly underneath the surface. Crystals and aggrega-
257 tions thereof were seen significantly in the system of FEL/HPMCAS-LF (Fig. 5c), but also from beneath
258 and on top of the surface in the formulation of FEL/HPMCAS-HF (Fig. 5d). In general, LSM suggested
259 occurrence of some crystals at early stability time (4 weeks, 40°C).

260

261 *3.5. Atomic force microscopy*

262 Atomic force microscopy (AFM) is another physical surface analysis method that reaches small fields of
263 view in a submicron range and is therefore complementary to LSM as a reference method of early stability
264 testing.

265 AFM topography (3D height) measurements were carried out to understand the morphology and growth
266 dynamics of the surface before and after storage. The representative micrographs are visible in Fig. 6. The
267 initial images show maximum height values of 100 nm (Fig. 6a) and 160 nm (Fig. 6b), respectively. Brighter
268 islands or domain regions, most likely corresponding to FEL-rich domains surrounded by HPMCAS-rich
269 domains, are indicated by peaks. The round edges of the FEL-rich domains indicate most likely that the
270 aggregated clusters were still coated with polymer; therefore, minor phase contrast can be differentiated

271 among these surfaces (Fig. 7a, b). These results are in line with previous literature [8]. AFM phase images
272 were recorded to obtain a contrast due to variation in energy dissipation, which is related to the presence of
273 differences in surface adherence and consequently different material properties. This technique also allows
274 detecting localized variations in stiffness, so even more details of morphology can be obtained by phase
275 contrast. Initial samples illustrate that the surfaces have a homogeneous contrast with brighter and darker
276 regions co-existing on the surface (Fig. 7a/b); hence material differences are less pronounced, assuming
277 that the polymer is dominating and/or amorphous domains of the drug prevail upon crystal growth.

278 On the other hand, after storage at accelerated conditions for 4 weeks, the surface topography (Fig. 6c/d)
279 shows a tendency to generally smoother (the height scale dropped to 14 nm and 30 nm, respectively), but
280 more heterogeneous surfaces in the sense of growing phase separation as seen in the phase contrast images
281 (Fig. 7c/d).

282 Both AFM modes (topography and phase imaging) strongly support each other and verify the obtained
283 results giving a very detailed insight into the nanoscopic morphology of the specimen.

284

285 **4. Discussion**

286 The metastable character of ASD is a hurdle for their development because re-crystallization during long-
287 term stability testing is a critical setback on the way to bring a drug product on the market. It is particularly
288 critical when such physical instability is only detected late in pharmaceutical development, whereas an
289 early identification of kinetically unstable formulations is less problematic in a screening phase. Accord-
290 ingly, there is a tremendous interest in early identification of drug phase separation and re-crystallization
291 from amorphous state. The present work is based on the hypothesis that multifractals can be helpful to early
292 detect instability in amorphous drug formulations. The selected model systems showed some physical
293 changes after four weeks with likely initial phase separation and occurrence of first crystals at the time of
294 four weeks where XRPD still could not detect any changes. It was in line with expectation that LSM and
295 AFM were more sensitive methods than XRPD to capture changes so these reference methods were inter-
296 esting to compare with the novel multifractal approach based on SEM-EDS imaging.

297

298 As a result, differences in the multifractal dimensions D_0 , D_1 , and D_2 were indeed evidenced after one
299 month compared to the initial analysis. Therefore, multifractals were capable of revealing microstructural
300 changes caused by instability that were otherwise hard to identify from the original images of SEM-EDS
301 and that were undetected by XRPD. Like any chemical imaging technique, SEM-EDS comes with spatial
302 resolution limits and they impact on the determined clusters [31]. Such clusters hold for drug-rich domains
303 and it is not possible to directly infer their physical state. These drug-rich regions can be of different kinds
304 [32], e.g. concentrated drug associated with polymer or it can be separate amorphous drug domains as well
305 as small crystal nuclei. This is important to keep in mind when clusters of drug are considered in the binary
306 images. Changes in these clusters are primarily changes in mathematical objects as captured by the fractal
307 dimensions, D_0 , D_1 , and D_2 . The physical interpretation of these clusters should be always in the context of
308 the applied imaging method. Since the multifractal dimensions provide meaning to cluster distributions
309 they can prove helpful for understanding any early changes in ASD.

310

311 The dimension D_0 describes a space-filling capacity [33] and values decreased in the early period of stability
312 testing. This result was not easy to predict because there are different possible processes like drug migration
313 to the surface that may increase the space-filling capacity. An increase could also come from drug that was
314 previously too dispersed and low concentrated to be detected as a drug-rich domain so that local aggregation
315 can lead to new clusters. While these are processes to increase D_0 , there are other effects leading to lowered
316 values of this capacity dimension. Some of the drug-rich domains of drug-polymer aggregates may locally
317 become more concentrated in an overall phase separation or drug re-crystallization. The resulting more
318 concentrated clusters would appear still white in the binary images so that overall space coverage could
319 slightly diminish.

320

321 The different cluster changes were apparently also leading on the average to a reduction in the information
322 dimension D_1 . This dimension reflects the diversity of elements in the system [29,34]. Moreover, D_2 holds

323 for a correlation dimension [29,30,35] and the evidenced reduction was caused by the microstructural
324 changes. Thinking of the transformation from amorphous clusters to crystals there is of course nucleation
325 as well as growth. Depending on which mechanism prevails, there would be different ways of how the
326 correlation dimension changes. Thinking of the microstructural processes of phase separation, or crystal
327 nucleation and growth, it is possible that different processes affect fractal dimensions in opposite directions,
328 which could entail a loss of discrimination. The sensitivity to detect early physical instability by the mul-
329 tifractal approach is therefore certainly depending on the physical processes that occur as well as on the
330 imaging technique used.

331
332 To compare the changes in cluster dynamic with other physical analysis methods, the sample surfaces were
333 also studied by means of LSM and AFM. LSM and AFM are popular microscopic techniques to study
334 surfaces with ultrahigh resolution [36,37]. While LSM can sample comparatively larger surfaces, AFM
335 provides sub-micron images of surface topography and phase imaging.

336
337 The initial LSM micrograph profiles (Fig. 5 a/b) of the surfaces were rather uneven and rough and both
338 formulations had rather similar surface texture while hardly no crystals were seen. Compared to the initial
339 rough micrographs it is evident in Figure 5 c/d that there was a structural re-arrangement of the surface
340 suggested likely caused by increased mobility [38]. The surfaces revealed in both formulations flat and
341 smooth areas, and curved rough regions in the underlying microstructure. It is suggested that after the stor-
342 age at 40°C, the temperature induced possible re-crystallization and aggregates of drug were formed, as can
343 be observed, small groups of crystals with regular shape grow towards the surface as a result of re-crystal-
344 lization.

345
346 Due to the small area of analysis, AFM was leading to individual view on a sub-micron scale. The initial
347 roughness is confirmed with a continuous matrix where critical spots of drug-rich domains might be occa-
348 sionally recognized (Fig. 6a/b), while after storage the topography of the surfaces looked generally a bit

349 smoother (Figure 6c/d). From phase imaging, it is suggested that initially (Fig. 7a/b) the drug and the pol-
350 ymer were remaining both in the amorphous state and showed more or less homogenous contrast in the
351 phase signal. The appearance of a brighter domain in the AFM phase image (Fig. 7c) give evidence of the
352 existence of crystalline domains among partially amorphous and highly dissipating polymer regions, indi-
353 cating a heterogeneous surface due to the phase separation. These findings seems contradictory at first sight,
354 but under assumption that amorphous regions of the drug are re-crystallizing with accelerating temperature,
355 the polymer needs to reorganize as well and starts to flatten out. This is in agreement with the relaxation
356 phenomenon and mobility in glass state [14].

357
358 The orthogonal techniques LSM and AFM would be in line with the assumption that crystalline-amorphous
359 phase separation may have occurred [32]. Based on this mechanism, a larger amount of drug can be uni-
360 formly de-mix and segregate in a short amount of time, while nucleation and growth act only locally [39].
361 The de-mixing was likely to accelerate re-crystallization of drug.

362
363 In summary, the finding of the orthogonal methods of SEM-EDS, LSM and AFM suggest that even the
364 freshly prepared solid dispersions had drug-rich and polymer-rich clusters and this heterogeneity was re-
365 flected in the binary images obtained from SEM-EDS. The subsequent dynamics of de-mixing and re-
366 crystallization was captured as complex changes in cluster dynamics of the binary images leading to meas-
367 urable changes in multifractal dimension, LSM and AFM images, whereas in the classical XRPD analysis
368 no changes were observed throughout the same time period.

369

370 **5. Conclusions**

371 The present work addressed the need for novel tools in early identification of physical instability of solid
372 dispersions. Multifractal analysis was introduced successfully to early stages of stability testing using amor-
373 phous solid dispersions. Changes in the fractal dimensions were noted early in stability testing, when no

374 changes were appreciated based on XRPD analysis. The orthogonal techniques of SEM-EDS, LSM and
375 AFM that are known to be sensitive for microstructural change, suggested that the initial solid dispersions
376 already displayed heterogeneity in terms of drug-rich and polymer-rich domains and de-mixing of the com-
377 ponents was likely to precede nucleation of crystalline material.

378
379 A decrease of the fractal dimensions D_0 , D_1 and D_2 was statistically significant after four weeks of stability
380 testing, while a possible effect of the HPMCAS grade was not revealed. Although the use of multifractals
381 was successful for early instability detection, care is needed to expect the same cluster dynamics in other
382 solid dispersions too. We discussed that different mechanisms of microstructural change can affect clusters
383 and therefore fractal dimensions. However, a clear strength of the presented data evaluation is that this
384 cluster analysis can be based even on more than one physical method of imaging. It could be, for example,
385 also used for imaging based on Raman or near infrared spectroscopy. Moreover, it would be interesting to
386 study different types of solid dispersions. The present work holds much promise but further research is
387 needed to better assess the capability of multifractals to act as early warning tool for physical changes in
388 metastable drug formulations.

389

390 **Acknowledgements**

391

392 Financial support to RAV from Brazilian Federal Agency for Support and Evaluation of Graduate Educa-
393 tion within the Ministry of Education of Brazil (CAPES) grant number 99999.001486 is greatly acknowl-
394 edged. We also thank Spanish Ministry of Economy and Competitiveness and FEDER Funds (European
395 Union) for the support of the project MAT2016-77345-C3-3-P

396

397 **Appendix: Multifractal theory**

399 The fractal dimension is measured by overlaying the binary image with grid of boxes and counting the
400 number of boxes, $N(\varepsilon)$, this is expressed as [23,27]

$$401 \quad N(\varepsilon) \sim \varepsilon^{-D_0} \quad (1)$$

402 where D_0 is the fractal dimension, calculated from the following equation:

$$403 \quad D_0 = \lim_{\varepsilon \rightarrow 0} \frac{\log N(\varepsilon)}{\log \frac{1}{\varepsilon}} \quad (2)$$

404 D_0 is derived by counting the number of boxes with various sizes to cover the image and then estimating
405 the linear region in the log-log plot. However, complex structures may not entirely be described by single
406 fractal dimension, but by multifractal analysis, which considers the amount of mass inside each box, in this
407 way characterize these complex structures. The probability P_i of finding the object pixel in the i^{th} box is
408 determined by

$$409 \quad P_i(\varepsilon) \sim \varepsilon^{\alpha_i} \quad (3)$$

410 where α_i is the singularity strength which corresponds to the density in the i^{th} box.

411 The probability distribution for multifractal measurements is

$$412 \quad \sum_i [P_i(\varepsilon)^q] \sim \varepsilon^{\tau(q)} \quad (4)$$

413 Where q is the exponent expressing the fractal properties in different scales of the object. $\tau(q)$ can be defined
414 as:

$$415 \quad \tau(q) = \lim_{\varepsilon \rightarrow 0} [\ln(\sum_i P_i(\varepsilon)^q)] / \ln(1/\varepsilon) \quad (5)$$

416 The full plot of D_q versus q is representative of the strength of the multifractality of finite measure, and the
417 generalized dimension D_q which is related with q can be expressed as

$$418 \quad D_q = \frac{\tau(q)}{(q-1)} \quad (6)$$

419 Also, the relationship between parameters of $f(\alpha)$ versus α are used to calculate the multifractal spectra:

$$420 \quad N(\alpha) \sim \varepsilon^{-f(\alpha)} \quad (7)$$

421 where the number of boxes $N(\alpha)$ for each probability $P_i(\mathcal{E})$ has singularity strengths between α and $\alpha + d\alpha$
422 is found to scale. $f(\alpha)$ against α , in general way it gives the “fractal dimension” $f(\alpha)$ of sets where the
423 measure scales locally with the same exponent α . The multifractal spectrum gives one dimension for each
424 set where the data scales similarly. The variable $f(\alpha(q))$ gives the local fractal dimension at resolution q .
425 $f(\alpha)$ has the same information of generalized information D_q and can be defined as [23,27,28]:

$$426 \quad f(\alpha(q)) = q\alpha(q) - \tau(q) \quad (8)$$

427 where $\alpha(q)$ can be defined as:

$$428 \quad \alpha(q) = \frac{d\tau(q)}{dq} \quad (9)$$

429 In case of monofractal, $D_0 = D_1 = D_2$, whereas different values $D_0 \geq D_1 \geq D_2$ indicate a multifractal system
430 [28].

431

432 **References**

433 [1] A. Newman, G. Knipp, G. Zografi, Assessing the Performance of Amorphous Solid Dispersions,
434 *IJOURNAL Pharm. Sci.* 101 (2012) 1355–1377.

435 [2] Y. Huang, W.-G. Dai, Fundamental aspects of solid dispersion technology for poorly soluble
436 drugs, *Acta Pharm. Sin. B.* 4 (2014) 18–25.

437 [3] S. Baghel, H. Cathcart, N.J. O’Reilly, Polymeric Amorphous Solid Dispersions: A Review of
438 Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous
439 Solubilization of Biopharmaceutical Classification System Class II Drugs, *J. Pharm. Sci.* 105
440 (2016) 2527–2544.

441 [4] N. Wyttenbach, M. Kuentz, Glass-forming ability of compounds in marketed amorphous drug
442 products, *Eur. J. Pharm. Biopharm.* 112 (2017) 204–208.

443 [5] J.B. Nanubolu, J.C. Burley, Investigating the recrystallisation behaviour of amorphous
444 paracetamol by variable temperature Raman studies and surface Raman mapping ., *Mol. Pharm.* 9
445 (2012) 1544–1558.

- 446 [6] P. Mistry, K.K. Amponsah-Efah, R. Suryanarayanan, Rapid Assessment of the Physical Stability
447 of Amorphous Solid Dispersions, *Cryst. Growth Des.* 17 (2017) 2478–2485.
- 448 [7] M. Milne, W. Liebenberg, M. Aucamp, The Stabilization of Amorphous Zopiclone in an
449 Amorphous Solid Dispersion, *AAPS PharmSciTech.* 16 (2015) 1190–1202.
- 450 [8] Z. Yang, K. Nollenberger, J. Albers, J. Moffat, D. Craig, S. Qi, The effect of processing on the
451 surface physical stability of amorphous solid dispersions, *Eur. J. Pharm. Biopharm.* 88 (2014)
452 897–908.
- 453 [9] E.O. Kissi, H. Grohganz, K. Löbmann, M.T. Ruggiero, J.A. Zeitler, T. Rades, Glass-Transition
454 Temperature of the β -Relaxation as the Major Predictive Parameter for Recrystallization of Neat
455 Amorphous Drugs, *J. Phys. Chem. B.* (2018) acs.jpcc.7b10105.
- 456 [10] J. Sibik, J.A. Zeitler, Direct measurement of molecular mobility and crystallisation of amorphous
457 pharmaceuticals using terahertz spectroscopy, *Adv. Drug Deliv. Rev.* 100 (2016) 147–157.
- 458 [11] G. Zografi, A. Newman, Interrelationships Between Structure and the Properties of Amorphous
459 Solids of Pharmaceutical Interest, *J. Pharm. Sci.* 106 (2017) 5–27.
- 460 [12] C. Correa-Soto, N.S. Trasi, P.D. Schmitt, Y. Su, Z. Liu, E. Miller, N. Variankaval, P.J. Marsac,
461 G.J. Simpson, L.S. Taylor, Second harmonic generation microscopy as a tool for the early
462 detection of crystallization in spray dried dispersions, *J. Pharm. Biomed. Anal.* 146 (2017) 86–95.
- 463 [13] N.K. Thakral, S. Mohapatra, G.A. Stephenson, R. Suryanarayanan, Compression-Induced
464 Crystallization of Amorphous Indomethacin in Tablets: Characterization of Spatial Heterogeneity
465 by Two- Dimensional X - ray Di ff ractometry, *Mol. Pharm.* 12 (2015) 253–263.
- 466 [14] M. Descamps, E. Dudognon, Crystallization from the amorphous state: Nucleation-growth
467 decoupling, polymorphism interplay, and the role of interfaces, *J. Pharm. Sci.* 103 (2014) 2615–
468 2628.
- 469 [15] N.L. Calvo, R.M. Maggio, T.S. Kaufman, Characterization of pharmaceutically relevant materials
470 at the solid state employing chemometrics methods, *J. Pharm. Biomed. Anal.* 147 (2018) 538–564.

- 471 [16] B. Vajna, H. Pataki, Z. Nagy, I. Farkas, G. Marosi, Characterization of melt extruded and
472 conventional Isoptin formulations using Raman chemical imaging and chemometrics, *Int. J.*
473 *Pharm.* 419 (2011) 107–113.
- 474 [17] S. Rades, V.-D. Hodoroaba, T. Salge, T. Wirth, M.P. Lobera, R.H. Labrador, K. Natte, T. Behnke,
475 T. Gross, W.E.S. Unger, High-resolution imaging with SEM/T-SEM, EDX and SAM as a
476 combined methodical approach for morphological and elemental analyses of single engineered
477 nanoparticles, *RSC Adv.* 4 (2014) 49577–49587.
- 478 [18] N. Scoutaris, K. Vithani, I. Slipper, B. Chowdhry, D. Douroumis, SEM/EDX and confocal Raman
479 microscopy as complementary tools for the characterization of pharmaceutical tablets, *Int. J.*
480 *Pharm.* 470 (2014) 88–98.
- 481 [19] S. Hellstén, H. Qu, T. Heikkilä, J. Kohonen, S.-P. Reinikainen, M. Louhi-Kultanen, Raman
482 spectroscopic imaging of indomethacin loaded in porous silica, *CrystEngComm.* 14 (2012) 1582–
483 1587.
- 484 [20] H. Ueda, Y. Ida, K. Kadota, Y. Tozuka, Raman mapping for kinetic analysis of crystallization of
485 amorphous drug based on distributional images, *Int. J. Pharm.* 462 (2014) 115–122.
- 486 [21] C. Demetzos, N. Pippa, Fractal analysis as a complementary approach to predict the stability of
487 drug delivery nano systems in aqueous and biological media: A regulatory proposal or a dream?,
488 *Int. J. Pharm.* 473 (2014) 213–218.
- 489 [22] W. Kirchmeyer, N. Wytttenbach, J. Alsenz, M. Kuentz, Influence of excipients on solvent-
490 mediated hydrate formation of piroxicam studied by dynamic imaging and fractal analysis, *Cryst.*
491 *Growth Des.* 15 (2015) 5002–5010.
- 492 [23] K. Liu, M. Ostadhassan, Quantification of the microstructures of Bakken shale reservoirs using
493 multi-fractal and lacunarity analysis, *J. Nat. Gas Sci. Eng.* 39 (2017) 62–71.
- 494 [24] C. Adler, A. Teleki, M. Kuentz, Multifractal Characterization of Pharmaceutical Hot-Melt
495 Extrudates, *Pharm. Res.* 34 (2017) 321–332.

- 496 [25] R. Abreu-Villela, C. Adler, I. Caraballo, M. Kuentz, Electron microscopy/energy dispersive X-ray
497 spectroscopy of drug distribution in solid dispersions and interpretation by multifractal geometry,
498 *J. Pharm. Biomed. Anal.* 150 (2018) 241–247.
- 499 [26] Shin Etsu, Hypromellose Acetate Succinate NF Technical Information, *Usp Nf.*, (2005) 1–20.
- 500 [27] D.J. Gould, T.J. Vadakkan, R.A. Poché, Dj.M.E. Dickinson, Multifractal and Lacunarity Analysis
501 of Microvascular Morphology and Remodeling, (2011) 136–151.
- 502 [28] H. Salat, R. Murcio, E. Arcaute, Multifractal methodology, *Physica A.* 473 (2017) 467–487.
- 503 [29] A. Giri, S. Tarafdar, P. Gouze, T. Dutta, Multifractal analysis of the pore space of real and
504 simulated sedimentary rocks, *Geophys. J. Int.* 200 (2015) 1106–1115.
- 505 [30] T. Kano, Y. Yoshihashi, E. Yonemochi, K. Terada, Clarifying the mechanism of aggregation of
506 particles in high-shear granulation based on their surface properties by using micro-spectroscopy,
507 *Int. J. Pharm.* 461 (2014) 495–504.
- 508 [31] Ž. Mitić, A. Stolić, S. Stojanović, S. Najman, N. Ignjatović, G. Nikolić, M. Trajanović,
509 Instrumental methods and techniques for structural and physicochemical characterization of
510 biomaterials and bone tissue: A review, *Mater. Sci. Eng. C.* 79 (2017) 930–949.
- 511 [32] D.J. Van Drooge, K. Braeckmans, W.L.J. Hinrichs, K. Remaut, S.C. De Smedt, H.W. Frijlink,
512 Characterization of the mode of incorporation of lipophilic compounds in solid dispersions at the
513 nanoscale using Fluorescence Resonance Energy Transfer (FRET), *Macromol. Rapid Commun.*
514 27 (2006) 1149–1155.
- 515 [33] N. Pippa, S. Pispas, C. Demetzos, The fractal hologram and elucidation of the structure of
516 liposomal carriers in aqueous and biological media, *Int. J. Pharm.* 430 (2012) 65–73.
- 517 [34] Y. Chen, J. Wang, J. Feng, Understanding the fractal dimensions of urban forms through spatial
518 entropy, *Entropy.* 19 (2017) 1–18. doi:10.3390/e19110600.
- 519 [35] K. Izawa, N. Hattori, H. Okabayashi, Growth process for fractal polymer aggregates formed by

- 520 perfluorooctyltrimethoxysilane . Time-resolved small-angle X-ray scattering study, *Colloid*
521 *Polym. Sci.* 278 (2000) 293–300.
- 522 [36] J. Ofner, F. Brenner, K. Wieland, E. Eitenberger, J. Kirschner, C. Eisenmenger-Sittner, S. Török,
523 B. Döme, T. Konegger, A. Kasper-Giebl, H. Hutter, G. Friedbacher, B. Lendl, H. Lohninger,
524 Image-Based Chemical Structure Determination, *Sci. Rep.* 7 (2017) 1–11.
- 525 [37] Y. Chen, Data fusion for accurate microscopic rough surface metrology, *Ultramicroscopy.* 165
526 (2016) 15–25.
- 527 [38] H.X. Guo, J. Heinämäki, J. Yliruusi, Characterization of particle deformation during compression
528 measured by confocal laser scanning microscopy, *Int. J. Pharm.* 186 (1999) 99–108.
- 529 [39] M.E. Lauer, M. Siam, J. Tardio, S. Page, J.H. Kindt, O. Grassmann, Rapid Assessment of
530 Homogeneity and Stability of Amorphous Solid Dispersions by Atomic Force Microscopy—From
531 Bench to Batch, *Pharm. Res.* 30 (2013) 2010–2022.

532

533

534 **Figure captions**

535

536 Fig. 1. Chemical structures of felodipine (FEL) and HPMCAS.

537

538 Fig. 2. Powder X-ray diffraction of FEL in physical mixture (PM) with HPMCAS of different polymer
539 grades and formulated as amorphous solid dispersion (ASD). From bottom to top: ASDs: FEL/HPMCAS-
540 LF, FEL/HPMCAS-HF after 4 weeks stored at 40°C; PM: FEL/HPMCAS-LF, FEL/HPMCAS-HF (all sam-
541 ples at a drug load of 50 wt% of FEL).

542

543 Fig. 3. Results of energy dispersive X-ray spectroscopy (EDS) to obtain two-dimensional binary images of
544 ASDs FEL/HPMCAS-LF, FEL/HPMCAS-HF (50 wt% of FEL), following storage at 40°C. Drug-rich
545 phase is shown as white domains.

546

547 Fig. 4. Statistical means plot of FEL/HPMCAS ASD formulations (50 wt% of FEL) based on a two-factor
548 ANOVA of how D_0 (a) and D_2 (b) are affected by storage time (at 40°C), and intervals of Fisher's Least
549 Significant Difference (LSD, 95%) are shown.

550

551 Fig. 5. Confocal laser microscopy of ASDs before storage (a, b) and after storage (c, d) for 4 weeks at 40°C.
552 FEL/HPMCAS-LF (a, c), FEL/HPMCAS-HF (b, d), at 50 wt% of FEL. The scale bar is 10 μm.

553

554 Fig. 6. AFM topographical images of FEL/HPMCAS ASDs before storage (a, b) and after storage (c, d)
555 for 4 weeks at 40°C. FEL/HPMCAS-LF (a, c) and FEL/HPMCAS-HF (b, d).

556

557 Fig. 7. AFM phase images of FEL/HPMCAS ASDs; before (a, b) and after storage (c, d) for 4 weeks at
558 40°C. FEL/HPMCAS-LF (a, c) and FEL/HPMCAS-HF (b, d).

559

Table 1

Generalized fractal dimensions of felodipine (FEL) solid dispersions over time as based on chemical imaging and conversion to binary pictures.

	Age (week)	Generalized fractal dimensions		
		D_0	D_1	D_2
FEL/HPMCAS-LF (50:50)	0	1.92 ± 0.01	1.88 ± 0.01	1.81 ± 0.02
	2	1.92 ± 0.01	1.88 ± 0.01	1.81 ± 0.02
	4	1.91 ± 0.01	1.86 ± 0.01	1.79 ± 0.01
FEL/HPMCAS-HF (50:50)	0	1.93 ± 0.00	1.89 ± 0.00	1.82 ± 0.01
	2	1.92 ± 0.01	1.88 ± 0.01	1.81 ± 0.02
	4	1.91 ± 0.01	1.87 ± 0.02	1.80 ± 0.02